Comment in

• Exploitation of Sulfated Glycosaminoglycan Status for Precision Medicine of Triplatin in Triple-Negative Breast Cancer.

  Hampton JD, Peterson EJ, Katner SJ, Turner TH, Alzubi MA, Harrell JC, Dozmorov MG, Turner JBM, Gigliotti PJ, Kraskauskiene V, Shende M, Idowu MO, Puchalapalli M, Hu B, Litovchick L, Katsuta E, Takabe K, Farrell NP, Koblinski JE. Hampton JD, et al. Mol Cancer Ther. 2022 Feb;21(2):271-281. doi: 10.1158/1535-7163.MCT-20-0969. Epub 2021 Nov 23. Mol Cancer Ther. 2022. PMID: 34815360 Free PMC article.
• Abdominopelvic FLASH Irradiation Improves PD-1 Immune Checkpoint Inhibition in Preclinical Models of Ovarian Cancer.

  Eggold JT, Chow S, Melemenidis S, Wang J, Natarajan S, Loo PE, Manjappa R, Viswanathan V, Kidd EA, Engleman E, Dorigo O, Loo BW, Rankin EB. Eggold JT, et al. Mol Cancer Ther. 2022 Feb;21(2):371-381. doi: 10.1158/1535-7163.MCT-21-0358. Epub 2021 Dec 5. Mol Cancer Ther. 2022. PMID: 34866044 Free PMC article.
• RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors.

  Roulston A, Zimmermann M, Papp R, Skeldon A, Pellerin C, Dumas-Bérube É, Dumais V, Dorich S, Fader LD, Fournier S, Li L, Leclaire ME, Yin SY, Chefson A, Alam H, Yang W, Fugère-Desjardins C, Vignini-Hammond S, Skorey K, Mulani A, Rimkunas V, Veloso A, Hamel M, Stocco R, Mamane Y, Li Z, Young JTF, Zinda M, Black WC. Roulston A, et al. Mol Cancer Ther. 2022 Feb;21(2):245-256. doi: 10.1158/1535-7163.MCT-21-0615. Epub 2021 Dec 15. Mol Cancer Ther. 2022. PMID: 34911817 Free PMC article.
• Cellular-Resolution Imaging of Bystander Payload Tissue Penetration from Antibody-Drug Conjugates.

  Khera E, Dong S, Huang H, de Bever L, van Delft FL, Thurber GM. Khera E, et al. Mol Cancer Ther. 2022 Feb;21(2):310-321. doi: 10.1158/1535-7163.MCT-21-0580. Epub 2021 Dec 15. Mol Cancer Ther. 2022. PMID: 34911819 Free PMC article.